Compare Dropbox Inc (DBX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dropbox Inc vs Summit Therapeutics Inc — how do they compare? Dropbox Inc trades at $34.36 (market cap $7.42B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Dropbox Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dropbox Inc for 97 Days and Summit Therapeutics Inc for 16 Days on average.
| DBX | SMMT | |
|---|---|---|
Market Cap | $7.42B | $13.71B |
Volume | 3,061,580 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $37.74 | $26.38 |
52-Week Low | $22.06 | $12.43 |
Typical Hold Time | 97 Days | 16 Days |
Enterprise Value | $10.29B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dropbox (DBX) trades at $34.14, up 3.2% today, with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable near $2.5B annually, while net income margin improved to 20.16% in 2025. However, negative shareholder equity and high debt levels pose fundamental concerns, and recent insider selling and a mixed analyst consensus indicate cautious sentiment.
The outlook is mixed: strong profitability and cash flow support valuation, but stagnant growth and insider disposals suggest limited upside. Key risks include competitive pressure in cloud storage and execution challenges. Investors should weigh solid fundamentals against sentiment headwinds.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
